Cargando…
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262051/ https://www.ncbi.nlm.nih.gov/pubmed/30524291 http://dx.doi.org/10.3389/fphar.2018.01371 |
_version_ | 1783375034625032192 |
---|---|
author | Sui, Xinbing Zhang, Ruonan Liu, Shuiping Duan, Ting Zhai, Lijuan Zhang, Mingming Han, Xuemeng Xiang, Yu Huang, Xingxing Lin, Haoming Xie, Tian |
author_facet | Sui, Xinbing Zhang, Ruonan Liu, Shuiping Duan, Ting Zhai, Lijuan Zhang, Mingming Han, Xuemeng Xiang, Yu Huang, Xingxing Lin, Haoming Xie, Tian |
author_sort | Sui, Xinbing |
collection | PubMed |
description | Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging in specific cancer types; however, its relevance in colorectal cancer (CRC) is unexplored and remains unclear. Here, we showed that ferroptosis inducer RSL3 initiated cell death and ROS accumulation in HCT116, LoVo, and HT29 CRC cells over a 24 h time course. Furthermore, we found that ROS levels and transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of glutathione peroxidase 4 (GPX4), indicating an iron-dependent cell death, ferroptosis. Overexpression GPX4 resulted in decreased cell death after RSL3 treatment. Therefore, RSL3 was able to induce ferroptosis on three different CRC cell lines in vitro in a dose- and time-dependent manner, which was due to increased ROS and an increase in the cellular labile iron pool. Moreover, this effect was able to be reversed by overexpression of GPX4. Taken together, our results suggest that the induction of ferroptosis contributed to RSL3-induced cell death in CRC cells and ferroptosis may be a pervasive and dynamic form of cell death for cancer treatment. |
format | Online Article Text |
id | pubmed-6262051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62620512018-12-06 RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer Sui, Xinbing Zhang, Ruonan Liu, Shuiping Duan, Ting Zhai, Lijuan Zhang, Mingming Han, Xuemeng Xiang, Yu Huang, Xingxing Lin, Haoming Xie, Tian Front Pharmacol Pharmacology Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging in specific cancer types; however, its relevance in colorectal cancer (CRC) is unexplored and remains unclear. Here, we showed that ferroptosis inducer RSL3 initiated cell death and ROS accumulation in HCT116, LoVo, and HT29 CRC cells over a 24 h time course. Furthermore, we found that ROS levels and transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of glutathione peroxidase 4 (GPX4), indicating an iron-dependent cell death, ferroptosis. Overexpression GPX4 resulted in decreased cell death after RSL3 treatment. Therefore, RSL3 was able to induce ferroptosis on three different CRC cell lines in vitro in a dose- and time-dependent manner, which was due to increased ROS and an increase in the cellular labile iron pool. Moreover, this effect was able to be reversed by overexpression of GPX4. Taken together, our results suggest that the induction of ferroptosis contributed to RSL3-induced cell death in CRC cells and ferroptosis may be a pervasive and dynamic form of cell death for cancer treatment. Frontiers Media S.A. 2018-11-22 /pmc/articles/PMC6262051/ /pubmed/30524291 http://dx.doi.org/10.3389/fphar.2018.01371 Text en Copyright © 2018 Sui, Zhang, Liu, Duan, Zhai, Zhang, Han, Xiang, Huang, Lin and Xie. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sui, Xinbing Zhang, Ruonan Liu, Shuiping Duan, Ting Zhai, Lijuan Zhang, Mingming Han, Xuemeng Xiang, Yu Huang, Xingxing Lin, Haoming Xie, Tian RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title | RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title_full | RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title_fullStr | RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title_full_unstemmed | RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title_short | RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer |
title_sort | rsl3 drives ferroptosis through gpx4 inactivation and ros production in colorectal cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262051/ https://www.ncbi.nlm.nih.gov/pubmed/30524291 http://dx.doi.org/10.3389/fphar.2018.01371 |
work_keys_str_mv | AT suixinbing rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT zhangruonan rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT liushuiping rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT duanting rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT zhailijuan rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT zhangmingming rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT hanxuemeng rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT xiangyu rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT huangxingxing rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT linhaoming rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer AT xietian rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer |